SCT520FF

Asset

Inhibits VEGF-mediated angiogenesis in the retina.

Stage
Phase 1
Modality
Antibody
Target
Not known
1
Indication
1
Trial
1
Developer

Trial NCT06672536 is still running. Trial NCT06672536 updated in its registry on Sep 4, 2025. clinicaltrials.gov

Indications

1

In the full profile

  • Owner and partners1
  • Trials1
  • Competitors1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets